Prognostic value of the FUT family in acute myeloid leukemia
Genetic abnormalities are more frequently viewed as prognostic markers in acute myeloid leukemia (AML) in recent years. Fucosylation, catalyzed by fucosyltransferases (FUTs), is a post-translational modification that widely exists in cancer cells. However, the expression and clinical implication of...
Gespeichert in:
| Veröffentlicht in: | Cancer gene therapy 2020-02, Vol.27 (1-2), p.70-80 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 80 |
|---|---|
| container_issue | 1-2 |
| container_start_page | 70 |
| container_title | Cancer gene therapy |
| container_volume | 27 |
| creator | Dai, Yifeng Cheng, Zhiheng Pang, Yifan Jiao, Yang Qian, Tingting Quan, Liang Cui, Longzhen Liu, Yan Si, Chaozeng Chen, Jinghong Ye, Xu Chen, Jingqi Shi, Jinlong Wu, Depei Zhang, Xinyou Fu, Lin |
| description | Genetic abnormalities are more frequently viewed as prognostic markers in acute myeloid leukemia (AML) in recent years. Fucosylation, catalyzed by fucosyltransferases (FUTs), is a post-translational modification that widely exists in cancer cells. However, the expression and clinical implication of the
FUT
family (
FUT1-11
) in AML has not been investigated. From the Cancer Genome Atlas database, a total of 155 AML patients with complete clinical characteristics and
FUT1-11
expression data were included in our study. In patients who received chemotherapy alone showed that high expression levels of
FUT3
,
FUT6
, and
FUT7
had adverse effects on event-free survival (EFS) and overall survival (OS) (all
P
|
| doi_str_mv | 10.1038/s41417-019-0115-9 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2242834923</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A614109202</galeid><sourcerecordid>A614109202</sourcerecordid><originalsourceid>FETCH-LOGICAL-c470t-887cd1edad2c9541304f84ccdadd89c1e436a599cb86b2402cbd91f15214ffa43</originalsourceid><addsrcrecordid>eNp1kV9LHDEUxUOx1NX2A_RFAoL4MjY3yfwJ-CJS24LQPuhzyGZudmMzE01mhP32zbK21lIJIXDv7xxy7yHkI7AzYKL7lCVIaCsGqlyoK_WGLEC2TVXXjO2RBVNcVaCY2CcHOd8xVpqteEf2BfDSa5oFOf-R4mqMefKWPpowI42OTmukV7c31JnBhw31IzV2npAOGwzR9zTg_BMHb96Tt86EjB-e3kNye_X55vJrdf39y7fLi-vKypZNVde1tgfsTc-tqiUIJl0nrS2FvlMWUIrG1ErZZdcsuWTcLnsFDmoO0jkjxSE53fnep_gwY5704LPFEMyIcc6ac8k7IRUXBT3-B72LcxrL7zQXddOIVrT8mVqZgNqPLk7J2K2pvmjKTsty2JY6-w9VTl-Gt3FE50v9heDkL8EaTZjWOYZ58nHML0HYgTbFnBM6fZ_8YNJGA9PbaPUuWl2i1dtotSqao6fJ5uWA_R_F7ywLwHdALq1xhel59NddfwETZaoH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2356637372</pqid></control><display><type>article</type><title>Prognostic value of the FUT family in acute myeloid leukemia</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Dai, Yifeng ; Cheng, Zhiheng ; Pang, Yifan ; Jiao, Yang ; Qian, Tingting ; Quan, Liang ; Cui, Longzhen ; Liu, Yan ; Si, Chaozeng ; Chen, Jinghong ; Ye, Xu ; Chen, Jingqi ; Shi, Jinlong ; Wu, Depei ; Zhang, Xinyou ; Fu, Lin</creator><creatorcontrib>Dai, Yifeng ; Cheng, Zhiheng ; Pang, Yifan ; Jiao, Yang ; Qian, Tingting ; Quan, Liang ; Cui, Longzhen ; Liu, Yan ; Si, Chaozeng ; Chen, Jinghong ; Ye, Xu ; Chen, Jingqi ; Shi, Jinlong ; Wu, Depei ; Zhang, Xinyou ; Fu, Lin</creatorcontrib><description>Genetic abnormalities are more frequently viewed as prognostic markers in acute myeloid leukemia (AML) in recent years. Fucosylation, catalyzed by fucosyltransferases (FUTs), is a post-translational modification that widely exists in cancer cells. However, the expression and clinical implication of the
FUT
family (
FUT1-11
) in AML has not been investigated. From the Cancer Genome Atlas database, a total of 155 AML patients with complete clinical characteristics and
FUT1-11
expression data were included in our study. In patients who received chemotherapy alone showed that high expression levels of
FUT3
,
FUT6
, and
FUT7
had adverse effects on event-free survival (EFS) and overall survival (OS) (all
P
< 0.05), whereas high
FUT4
expression had favorable effects on EFS and OS (all
P
< 0.01). However, in the allogeneic hematopoietic stem cell transplantation (allo-HSCT) group, we only found a significant difference in EFS between the high and low
FUT3
expression subgroups (
P
= 0.047), while other
FUT
members had no effect on survival. Multivariate analysis confirmed that high
FUT4
expression was an independent favorable prognostic factor for both EFS (HR = 0.423,
P
= 0.001) and OS (HR = 0.398,
P
< 0.001), whereas high
FUT6
expression was an independent risk factor for both EFS (HR = 1.871,
P
= 0.017) and OS (HR = 1.729,
P
= 0.028) in patients who received chemotherapy alone. Moreover, we found that patients with low
FUT4
and high
FUT6
expressions had the shortest EFS and OS (
P
< 0.05). Our study suggests that high expressions of
FUT3/6/7
predict poor prognosis, high
FUT4
expression indicates good prognosis in AML;
FUT6
and
FUT4
have the best prognosticating profile among them, but their effects could be neutralized by allo-HSCT.</description><identifier>ISSN: 0929-1903</identifier><identifier>EISSN: 1476-5500</identifier><identifier>DOI: 10.1038/s41417-019-0115-9</identifier><identifier>PMID: 31209266</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>631/67/1990/283 ; 692/53 ; Acute myeloid leukemia ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biomedical and Life Sciences ; Biomedicine ; Bone Marrow - pathology ; Cancer ; Chemotherapy ; Disease-Free Survival ; Female ; Follow-Up Studies ; Fucosyltransferases - genetics ; Gene Expression ; Gene Expression Regulation, Leukemic ; Gene Therapy ; Genetic aspects ; Genomes ; Hematopoietic Stem Cell Transplantation ; Hematopoietic stem cells ; Humans ; Kaplan-Meier Estimate ; Leukemia ; Leukemia, Myeloid, Acute - genetics ; Leukemia, Myeloid, Acute - mortality ; Leukemia, Myeloid, Acute - pathology ; Leukemia, Myeloid, Acute - therapy ; Male ; Medical prognosis ; Medical research ; Medicine, Experimental ; Middle Aged ; Multivariate analysis ; Myeloid leukemia ; Neoplasm Recurrence, Local - epidemiology ; Neoplasm Recurrence, Local - genetics ; Post-translation ; Prognosis ; Risk Factors ; Stem cell transplantation ; Transplantation ; Transplantation, Homologous ; Young Adult</subject><ispartof>Cancer gene therapy, 2020-02, Vol.27 (1-2), p.70-80</ispartof><rights>The Author(s), under exclusive licence to Springer Nature America, Inc. 2019</rights><rights>COPYRIGHT 2020 Nature Publishing Group</rights><rights>2019© The Author(s), under exclusive licence to Springer Nature America, Inc. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c470t-887cd1edad2c9541304f84ccdadd89c1e436a599cb86b2402cbd91f15214ffa43</citedby><cites>FETCH-LOGICAL-c470t-887cd1edad2c9541304f84ccdadd89c1e436a599cb86b2402cbd91f15214ffa43</cites><orcidid>0000-0002-1077-6422 ; 0000-0001-8837-9542 ; 0000-0002-2416-7572 ; 0000-0003-3507-7414 ; 0000-0002-0478-4952</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41417-019-0115-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41417-019-0115-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31209266$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dai, Yifeng</creatorcontrib><creatorcontrib>Cheng, Zhiheng</creatorcontrib><creatorcontrib>Pang, Yifan</creatorcontrib><creatorcontrib>Jiao, Yang</creatorcontrib><creatorcontrib>Qian, Tingting</creatorcontrib><creatorcontrib>Quan, Liang</creatorcontrib><creatorcontrib>Cui, Longzhen</creatorcontrib><creatorcontrib>Liu, Yan</creatorcontrib><creatorcontrib>Si, Chaozeng</creatorcontrib><creatorcontrib>Chen, Jinghong</creatorcontrib><creatorcontrib>Ye, Xu</creatorcontrib><creatorcontrib>Chen, Jingqi</creatorcontrib><creatorcontrib>Shi, Jinlong</creatorcontrib><creatorcontrib>Wu, Depei</creatorcontrib><creatorcontrib>Zhang, Xinyou</creatorcontrib><creatorcontrib>Fu, Lin</creatorcontrib><title>Prognostic value of the FUT family in acute myeloid leukemia</title><title>Cancer gene therapy</title><addtitle>Cancer Gene Ther</addtitle><addtitle>Cancer Gene Ther</addtitle><description>Genetic abnormalities are more frequently viewed as prognostic markers in acute myeloid leukemia (AML) in recent years. Fucosylation, catalyzed by fucosyltransferases (FUTs), is a post-translational modification that widely exists in cancer cells. However, the expression and clinical implication of the
FUT
family (
FUT1-11
) in AML has not been investigated. From the Cancer Genome Atlas database, a total of 155 AML patients with complete clinical characteristics and
FUT1-11
expression data were included in our study. In patients who received chemotherapy alone showed that high expression levels of
FUT3
,
FUT6
, and
FUT7
had adverse effects on event-free survival (EFS) and overall survival (OS) (all
P
< 0.05), whereas high
FUT4
expression had favorable effects on EFS and OS (all
P
< 0.01). However, in the allogeneic hematopoietic stem cell transplantation (allo-HSCT) group, we only found a significant difference in EFS between the high and low
FUT3
expression subgroups (
P
= 0.047), while other
FUT
members had no effect on survival. Multivariate analysis confirmed that high
FUT4
expression was an independent favorable prognostic factor for both EFS (HR = 0.423,
P
= 0.001) and OS (HR = 0.398,
P
< 0.001), whereas high
FUT6
expression was an independent risk factor for both EFS (HR = 1.871,
P
= 0.017) and OS (HR = 1.729,
P
= 0.028) in patients who received chemotherapy alone. Moreover, we found that patients with low
FUT4
and high
FUT6
expressions had the shortest EFS and OS (
P
< 0.05). Our study suggests that high expressions of
FUT3/6/7
predict poor prognosis, high
FUT4
expression indicates good prognosis in AML;
FUT6
and
FUT4
have the best prognosticating profile among them, but their effects could be neutralized by allo-HSCT.</description><subject>631/67/1990/283</subject><subject>692/53</subject><subject>Acute myeloid leukemia</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Bone Marrow - pathology</subject><subject>Cancer</subject><subject>Chemotherapy</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Fucosyltransferases - genetics</subject><subject>Gene Expression</subject><subject>Gene Expression Regulation, Leukemic</subject><subject>Gene Therapy</subject><subject>Genetic aspects</subject><subject>Genomes</subject><subject>Hematopoietic Stem Cell Transplantation</subject><subject>Hematopoietic stem cells</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Leukemia</subject><subject>Leukemia, Myeloid, Acute - genetics</subject><subject>Leukemia, Myeloid, Acute - mortality</subject><subject>Leukemia, Myeloid, Acute - pathology</subject><subject>Leukemia, Myeloid, Acute - therapy</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Middle Aged</subject><subject>Multivariate analysis</subject><subject>Myeloid leukemia</subject><subject>Neoplasm Recurrence, Local - epidemiology</subject><subject>Neoplasm Recurrence, Local - genetics</subject><subject>Post-translation</subject><subject>Prognosis</subject><subject>Risk Factors</subject><subject>Stem cell transplantation</subject><subject>Transplantation</subject><subject>Transplantation, Homologous</subject><subject>Young Adult</subject><issn>0929-1903</issn><issn>1476-5500</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kV9LHDEUxUOx1NX2A_RFAoL4MjY3yfwJ-CJS24LQPuhzyGZudmMzE01mhP32zbK21lIJIXDv7xxy7yHkI7AzYKL7lCVIaCsGqlyoK_WGLEC2TVXXjO2RBVNcVaCY2CcHOd8xVpqteEf2BfDSa5oFOf-R4mqMefKWPpowI42OTmukV7c31JnBhw31IzV2npAOGwzR9zTg_BMHb96Tt86EjB-e3kNye_X55vJrdf39y7fLi-vKypZNVde1tgfsTc-tqiUIJl0nrS2FvlMWUIrG1ErZZdcsuWTcLnsFDmoO0jkjxSE53fnep_gwY5704LPFEMyIcc6ac8k7IRUXBT3-B72LcxrL7zQXddOIVrT8mVqZgNqPLk7J2K2pvmjKTsty2JY6-w9VTl-Gt3FE50v9heDkL8EaTZjWOYZ58nHML0HYgTbFnBM6fZ_8YNJGA9PbaPUuWl2i1dtotSqao6fJ5uWA_R_F7ywLwHdALq1xhel59NddfwETZaoH</recordid><startdate>20200201</startdate><enddate>20200201</enddate><creator>Dai, Yifeng</creator><creator>Cheng, Zhiheng</creator><creator>Pang, Yifan</creator><creator>Jiao, Yang</creator><creator>Qian, Tingting</creator><creator>Quan, Liang</creator><creator>Cui, Longzhen</creator><creator>Liu, Yan</creator><creator>Si, Chaozeng</creator><creator>Chen, Jinghong</creator><creator>Ye, Xu</creator><creator>Chen, Jingqi</creator><creator>Shi, Jinlong</creator><creator>Wu, Depei</creator><creator>Zhang, Xinyou</creator><creator>Fu, Lin</creator><general>Nature Publishing Group US</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1077-6422</orcidid><orcidid>https://orcid.org/0000-0001-8837-9542</orcidid><orcidid>https://orcid.org/0000-0002-2416-7572</orcidid><orcidid>https://orcid.org/0000-0003-3507-7414</orcidid><orcidid>https://orcid.org/0000-0002-0478-4952</orcidid></search><sort><creationdate>20200201</creationdate><title>Prognostic value of the FUT family in acute myeloid leukemia</title><author>Dai, Yifeng ; Cheng, Zhiheng ; Pang, Yifan ; Jiao, Yang ; Qian, Tingting ; Quan, Liang ; Cui, Longzhen ; Liu, Yan ; Si, Chaozeng ; Chen, Jinghong ; Ye, Xu ; Chen, Jingqi ; Shi, Jinlong ; Wu, Depei ; Zhang, Xinyou ; Fu, Lin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c470t-887cd1edad2c9541304f84ccdadd89c1e436a599cb86b2402cbd91f15214ffa43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>631/67/1990/283</topic><topic>692/53</topic><topic>Acute myeloid leukemia</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Bone Marrow - pathology</topic><topic>Cancer</topic><topic>Chemotherapy</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Fucosyltransferases - genetics</topic><topic>Gene Expression</topic><topic>Gene Expression Regulation, Leukemic</topic><topic>Gene Therapy</topic><topic>Genetic aspects</topic><topic>Genomes</topic><topic>Hematopoietic Stem Cell Transplantation</topic><topic>Hematopoietic stem cells</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Leukemia</topic><topic>Leukemia, Myeloid, Acute - genetics</topic><topic>Leukemia, Myeloid, Acute - mortality</topic><topic>Leukemia, Myeloid, Acute - pathology</topic><topic>Leukemia, Myeloid, Acute - therapy</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Middle Aged</topic><topic>Multivariate analysis</topic><topic>Myeloid leukemia</topic><topic>Neoplasm Recurrence, Local - epidemiology</topic><topic>Neoplasm Recurrence, Local - genetics</topic><topic>Post-translation</topic><topic>Prognosis</topic><topic>Risk Factors</topic><topic>Stem cell transplantation</topic><topic>Transplantation</topic><topic>Transplantation, Homologous</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dai, Yifeng</creatorcontrib><creatorcontrib>Cheng, Zhiheng</creatorcontrib><creatorcontrib>Pang, Yifan</creatorcontrib><creatorcontrib>Jiao, Yang</creatorcontrib><creatorcontrib>Qian, Tingting</creatorcontrib><creatorcontrib>Quan, Liang</creatorcontrib><creatorcontrib>Cui, Longzhen</creatorcontrib><creatorcontrib>Liu, Yan</creatorcontrib><creatorcontrib>Si, Chaozeng</creatorcontrib><creatorcontrib>Chen, Jinghong</creatorcontrib><creatorcontrib>Ye, Xu</creatorcontrib><creatorcontrib>Chen, Jingqi</creatorcontrib><creatorcontrib>Shi, Jinlong</creatorcontrib><creatorcontrib>Wu, Depei</creatorcontrib><creatorcontrib>Zhang, Xinyou</creatorcontrib><creatorcontrib>Fu, Lin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer gene therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dai, Yifeng</au><au>Cheng, Zhiheng</au><au>Pang, Yifan</au><au>Jiao, Yang</au><au>Qian, Tingting</au><au>Quan, Liang</au><au>Cui, Longzhen</au><au>Liu, Yan</au><au>Si, Chaozeng</au><au>Chen, Jinghong</au><au>Ye, Xu</au><au>Chen, Jingqi</au><au>Shi, Jinlong</au><au>Wu, Depei</au><au>Zhang, Xinyou</au><au>Fu, Lin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic value of the FUT family in acute myeloid leukemia</atitle><jtitle>Cancer gene therapy</jtitle><stitle>Cancer Gene Ther</stitle><addtitle>Cancer Gene Ther</addtitle><date>2020-02-01</date><risdate>2020</risdate><volume>27</volume><issue>1-2</issue><spage>70</spage><epage>80</epage><pages>70-80</pages><issn>0929-1903</issn><eissn>1476-5500</eissn><abstract>Genetic abnormalities are more frequently viewed as prognostic markers in acute myeloid leukemia (AML) in recent years. Fucosylation, catalyzed by fucosyltransferases (FUTs), is a post-translational modification that widely exists in cancer cells. However, the expression and clinical implication of the
FUT
family (
FUT1-11
) in AML has not been investigated. From the Cancer Genome Atlas database, a total of 155 AML patients with complete clinical characteristics and
FUT1-11
expression data were included in our study. In patients who received chemotherapy alone showed that high expression levels of
FUT3
,
FUT6
, and
FUT7
had adverse effects on event-free survival (EFS) and overall survival (OS) (all
P
< 0.05), whereas high
FUT4
expression had favorable effects on EFS and OS (all
P
< 0.01). However, in the allogeneic hematopoietic stem cell transplantation (allo-HSCT) group, we only found a significant difference in EFS between the high and low
FUT3
expression subgroups (
P
= 0.047), while other
FUT
members had no effect on survival. Multivariate analysis confirmed that high
FUT4
expression was an independent favorable prognostic factor for both EFS (HR = 0.423,
P
= 0.001) and OS (HR = 0.398,
P
< 0.001), whereas high
FUT6
expression was an independent risk factor for both EFS (HR = 1.871,
P
= 0.017) and OS (HR = 1.729,
P
= 0.028) in patients who received chemotherapy alone. Moreover, we found that patients with low
FUT4
and high
FUT6
expressions had the shortest EFS and OS (
P
< 0.05). Our study suggests that high expressions of
FUT3/6/7
predict poor prognosis, high
FUT4
expression indicates good prognosis in AML;
FUT6
and
FUT4
have the best prognosticating profile among them, but their effects could be neutralized by allo-HSCT.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>31209266</pmid><doi>10.1038/s41417-019-0115-9</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-1077-6422</orcidid><orcidid>https://orcid.org/0000-0001-8837-9542</orcidid><orcidid>https://orcid.org/0000-0002-2416-7572</orcidid><orcidid>https://orcid.org/0000-0003-3507-7414</orcidid><orcidid>https://orcid.org/0000-0002-0478-4952</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0929-1903 |
| ispartof | Cancer gene therapy, 2020-02, Vol.27 (1-2), p.70-80 |
| issn | 0929-1903 1476-5500 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2242834923 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | 631/67/1990/283 692/53 Acute myeloid leukemia Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomedical and Life Sciences Biomedicine Bone Marrow - pathology Cancer Chemotherapy Disease-Free Survival Female Follow-Up Studies Fucosyltransferases - genetics Gene Expression Gene Expression Regulation, Leukemic Gene Therapy Genetic aspects Genomes Hematopoietic Stem Cell Transplantation Hematopoietic stem cells Humans Kaplan-Meier Estimate Leukemia Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - mortality Leukemia, Myeloid, Acute - pathology Leukemia, Myeloid, Acute - therapy Male Medical prognosis Medical research Medicine, Experimental Middle Aged Multivariate analysis Myeloid leukemia Neoplasm Recurrence, Local - epidemiology Neoplasm Recurrence, Local - genetics Post-translation Prognosis Risk Factors Stem cell transplantation Transplantation Transplantation, Homologous Young Adult |
| title | Prognostic value of the FUT family in acute myeloid leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T01%3A19%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20value%20of%20the%20FUT%20family%20in%20acute%20myeloid%20leukemia&rft.jtitle=Cancer%20gene%20therapy&rft.au=Dai,%20Yifeng&rft.date=2020-02-01&rft.volume=27&rft.issue=1-2&rft.spage=70&rft.epage=80&rft.pages=70-80&rft.issn=0929-1903&rft.eissn=1476-5500&rft_id=info:doi/10.1038/s41417-019-0115-9&rft_dat=%3Cgale_proqu%3EA614109202%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2356637372&rft_id=info:pmid/31209266&rft_galeid=A614109202&rfr_iscdi=true |